Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
GORXQ: Plan of bankruptcy effective. All shares cancelled.
http://www.otcbb.com/asp/dailylist_detail.asp?d=12/18/2013&mkt_ctg=NON-OTCBB
Much people is waiting good news from GORXQ, for invest more money. At least me.
dang went up 400% today= "Q" shock
New 52-week low 0.0021 was created today! Sell the CH11 pos scam at
the bid ASAP before it hits another new low 0.001 or even 0.0005...
GeoPharma files for Chapter 11
March 25, 2011
LARGO — GeoPharma Inc. (symbol: GORX), a Largo-based pharmaceutical manufacturer, is bankrupt. The company recently filed for protection under Chapter 11, documents filed with the U.S. Bankruptcy Court for the Middle District of Florida show.
Despite earning roughly $85 million in revenues between 2007 and 2009, the company posted combined net losses of $30 million over that time frame, according to the firm’s financial statements.
In August, Kotha Sekharam resigned from his position as the company’s president. Carole Dore-Falcone, the firm’s chief financial officer, resigned in November.
In its filing with the court, GeoPharma estimated its total assets between $1 million and $10 million, and its total liabilities between $10 million and $50 million. The firm also estimated that it has between 200 and 999 creditors.
The company’s current president and CEO is George Stuart.
Epic fail, expect triple zeros
Mostly people do not know what happened today and what will happen tomorrow. Tomorrow the ending Q added. The pos scam might hit 0.001.
Hmm, interesting, wonder why nobody else is dumping their shares?
Bankruptcy filed today! Sell at the bid ASAP before it is too late.
I bet 0.002 will be the bottom price which will be hit today or next
week!
$GORX is breaking out today. 0.05 x 0.06 +66%
Current Share Structure Calculation indicates 3.7M share float.
I'm not sure why nobody else has posted this information, unless everybody else already knows this already and I'm just late to the punch? Link to filing: GeoPharma Inc. (Form: SC 13G/A, Received: 02/11/2011 14:53:31) http://bit.ly/dHngsl
By adding up all the institutional holdings I came up with the 35.2% number. And supposedly insider's own 48.8% according to Yahoo Finance. With this information we can attempt to calculate the float, so here goes:
Outstanding Shares 23.4M
%held by insiders 48.80%
%held by institution 35.20%
TOTAL% of shares held by insiders & institutions 84.00%
Total Shares Held by insiders & institutions 19.7M
Tradeable shares remaining assuming insiders & institutions do not sell their positions (*FLOAT*) 23.4 - 19.7 = 3.7M
So to clarify, the FLOAT is 3.7M shares. (The smaller the float, the larger the upside breakout).
Here is the data to calculate the 35.2% institutional holding from the 13G SEC filing:
Percent of Class
WA beneficially owns 6.2 % of the company’s Common Stock.*
WMSA is deemed to beneficially own 1.8 % of the company’s Common Stock
WMSP is deemed to beneficially own 1.2 % of the company’s Common Stock
WMSFLP is deemed to beneficially own 1.2 % of the company’s Common Stock
WMSFLTD is deemed to beneficially own 1.2 % of the company’s Common Stock
FCP is deemed to beneficially own 0.6 % of the company’s Common Stock
WCFLP is deemed to beneficially own 0.6 % of the company’s Common Stock
WCFLTD is deemed to beneficially own 0.6 % of the company’s Common Stock
WCCAA is deemed to beneficially own 0.8 % of the company’s Common Stock
WCCAP is deemed to beneficially own 0.8 % of the company’s Common Stock
WCCAFLP is deemed to beneficially own 0.8 % of the company’s Common Stock
WCCAFLTD is deemed to beneficially own 0.8 % of the company’s Common Stock
WCRAA is deemed to beneficially own 0.7 % of the company’s Common Stock
WCRAP is deemed to beneficially own 0.4 % of the company’s Common Stock
WCRAFLP is deemed to beneficially own 0.4 % of the company’s Common Stock
WCRAFLTD is deemed to beneficially own 0.4 % of the company’s Common Stock
DP is deemed to beneficially own 0.3 % of the company’s Common Stock
WHHYFLP is deemed to beneficially own 0.3 % of the company’s Common Stock
WHHYFLTD is deemed to beneficially own 0.3 % of the company’s Common Stock
PSA is deemed to beneficially own 0.3 % of the company’s Common Stock
PSP is deemed to beneficially own 0.3 % of the company’s Common Stock
PSFLP is deemed to beneficially own 0.3 % of the company’s Common Stock
PSFLTD is deemed to beneficially own 0.3 % of the company’s Common Stock
WSOPA is deemed to beneficially own 2.4 % of the company’s Common Stock
WSOPBP is deemed to beneficially own 2.4 % of the company’s Common Stock
WSOPFLP is deemed to beneficially own 2.4 % of the company’s Common Stock
WSOPFLTD is deemed to beneficially own 2.4 % of the company’s Common Stock
WSOPFLPB is deemed to beneficially own 2.4 % of the company’s Common Stock
WSOPFLTDB is deemed to beneficially own 2.4 % of the company’s Common Stock
IAM beneficially owns 0.2 % of the company’s Common Stock.*
The percentage of Common Stock reportedly owned by each entity herein is based on 23,399,000 shares of outstanding Common Stock of the Company, which is the total number of shares issued and outstanding on February 11 th , 1010.
$GORX chart is set for a huge breakout! See my blog post here for my DD & chart. http://bit.ly/hcq3RK
It sounds like you are promoting this stock. Do you have some insider information too? haha
Dear Fellow Investors -- Reliable sources tell me that Belcher, Inc. has received approval from the FDA for Cephlaxin and Amoxicillin. This influences Geopharma significantly because of the "B" shares. In addition, I understand that a group of the largest investors have engaged a law firm to file a 13D. Apparently Carprophen was sold by Belcher and could have solved Geopharma's problems months ago before the reorganization. Looks like Senior Taneja orchestrated a self-beneficial deal for himself at the expense of the shareholders. As you probably already know in,a 13D members are given access to all books and records of the Company. They are committed to unwind what appears to be illegal, immoral and illicit behavior on behalf of the Senior Taneja.
The people involved have vowed to expose Taneja and his free spending and irresponsible actions, in addition to bringing suits against the Board of Directors and Taneja himself and anyone else involved who did not act in the best interests of the shareholders. More to follow.
Does anyone know the share structure for GORX?
GORX at 0.05c, will go to 0.31c
http://stockcharts.com/h-sc/ui?s=GORX&p=W&yr=2&mn=0&dy=0&id=p54860471182
8k today, On August 4, 2010, Dr. Rafick Henein resigned as a director of the Company.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the
Securities and Exchange Act of 1934
Date of Report (Date of earliest reported event): August 4, 2010
GEOPHARMA, INC.
(Exact name of registrant as specified in charter)
Florida 001-16185 59-2600232
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
6950 Bryan Dairy Road, Largo, Florida 33777
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (727) 544-8866
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
--------------------------------------------------------------------------------
ITEM 5.02. Departure of Directors or Certain Officers
On August 4, 2010, Dr. Rafick Henein resigned as a director of the Company.
2
--------------------------------------------------------------------------------
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorize
GEOPHARMA, INC.
Date: August 9, 2010
/s/ Mihir K. Taneja
Mihir K. Taneja
Chief Executive Officer
/s/ Carol Dore-Falcone
Carol Dore-Falcone
Senior Vice President and Chief Financial Officer
3
It appears that no one is around to celebrate that they have moved debts around from one hand to the other, gotta love florida businesses.
This stock does still trade @ .09 last time I looked.
This board is obviously dead since last post was May 19th.
They will prob show up on the otc where I have no interest.
Being delisted from NASDAQ doesn't mean it will cease to exist. I will be looking for an 8K from the company within days to discuss where they plan on trading.
From reading the 8K - GORX has(had) things in the works - revenues are always subject to actually making and selling something - but from what I read I would consider buying if it starts trading OTC - not at it's current pps of course.
I'll be watching closer to see next move. I like the fact that GORX refused to do a R/S as proposed by NASDAQ(they wanted them to R/S so GORX would still qualify to pay NASDAQ fees), it had nothing to do with whether the stock failed or not - ITS ALL ABOUT FEES - By leaving NASDAQ and their fees - GORX may have a brighter future.
Let me know if the parking lot ever starts filling up again.
For disclosure purposes: I never held a position in GORX - price never came down to my comfort level.
Thanks,,,I was wondering why the parking lots were empty.
As of May 17,2010 trading suspended and will be delisted per 8K dated May 14,2010.
You can find it on Pinksheets.com
This one may have been delisted.....I will remove the board if I find it was.
GeoPharma Reduces Senior Convertible Debt
LARGO, Fla., Apr 21, 2010 (GlobeNewswire via COMTEX News Network) -- GeoPharma, Inc. (Nasdaq:GORX) (the "Company") announced today that since December 31, 2009, it has reduced its 12% convertible debt (the "Debt") owed to Whitebox Pharmaceutical Growth Fund ("Whitebox") by approximately $1.7 million gross, or approximately $1.3 million net after the effect of the current quarterly principal accretion of interest. As of December 31, 2009, the Company owed Whitebox approximately $15.9 million and since that time, Whitebox has elected through common stock conversions, to convert $1.7 million of principal outstanding in exchange for the Company's $0.01 par value common stock. Whitebox has made several written conversion requests since December 31, 2009 in increments ranging from $100,000 - $250,000 as applied directly to the Debt's outstanding principal and as such, the Company has issued an approximate 5,160,000 common shares cumulatively since December 31, 2009 or 19.3% of the 26,695,735 total shares currently outstanding.
As previously disclosed in the Company's March 31, 2009 Form 10-K as filed June 30, 2009, in addition to as disclosed in the Company's filed, and shareholder approved, proxy for the 2009 Annual Meeting held March 30, 2010, the Company's executive management agreed effective January 1, 2009 to receive common stock in lieu of certain portions of their cash-based salaried compensation. In addition, the Company's board of directors also agreed to accept common stock in lieu of all of their cash-based compensation. All of this compensation was also included within accrued current liabilities as of December 31, 2009.
The above stock issuances subsequent to December 31, 2009 to Whitebox and to the Company's executive management and board of directors result in a decrease in current liabilities of approximately $1.3 million and a decrease of approximately $1.7 million, respectively, for a total liability reduction of approximately $3 million all of which results in an aggregate increase of $3 million in stockholders' equity.
ABOUT GEOPHARMA, INC.:
GeoPharma, Inc. is a rapidly growing Bio/Pharma company with a diversified business model participating in Pharmaceuticals, Contract Manufacturing, and Medical devices. The Pharma divisions specialize in the formulation of generic drugs for human and veterinary usage and the development of medical devices used by oncologists and other medical professionals. The Manufacturing division manufactures and packages generic drugs, nutraceuticals, cosmetics, and functional food products for companies worldwide. For further information visit the GeoPharma website at
!-202-456-1414 call the white house and let them know you are against the healthcare bill.This is our last chance to stop it!!!They vote this weekend
Nice buy,I realy would like to see some more news and get a nice run.
picked up 4k more today. eom
I averaged down on the shake this morning, low float has to be getting chewed up.
GeoPharma Announces the Acceptability of Their Largo Cephalosporin Plant
March 02, 2010: 11:27 AM ET
LARGO, Fla., March 2, 2010 (GLOBE NEWSWIRE) -- GeoPharma, Inc. (Nasdaq:GORX) (the "Company") announced today that the FDA Office of Compliance has completed the evaluation of its Largo, Florida manufacturing facility dedicated to the production of Cephalosporin antibiotics and has indicated, based on the adequacy of the Company's written response, that it is acceptable to manufacture upon FDA approval of its Cephalexin ANDA.
Commenting on the milestone GeoPharma CEO Mihir Taneja stated, "The approval of this facility has been long anticipated. We are so pleased to have finally gained the endorsement of our facility by the FDA and we look forward to the related Cephalexin ANDA approval during the fiscal year ending March 31, 2011. We have made dramatic in roads with regards to our relationships in these areas and believe the plant approval and pending ANDA approval will be beneficial to the future of the Company. In this morning's conference call we will be discussing the company financials as well as the plant approval and other pertinent information related to our business."
A conference call has been scheduled for Tuesday, March 2, 2010 at 11 a.m. Eastern time. The conference call will be hosted by GeoPharma, Inc. CEO Mihir Taneja and Sr. VP/CFO Carol Dore-Falcone. Participants may dial in 15 minutes before the call is set to begin to register. The dial in number for participants is 1-408-337-0124. The Conference Confirmation code is 60291243.
A replay of the call will be available from 2 p.m. ET on March 2nd, through Tuesday, March 16th. The Replay of the call may be heard by dialing 706-645-9291. The Replay Pass Code is 60291243. Participants may also choose to listen to the call via webcast through the link in the events and presentations section of the Investor Relations page of the GeoPharma website located at http://www.geopharmainc.com.
ABOUT GEOPHARMA, INC.:
GeoPharma, Inc. is a rapidly growing Bio/Pharma company with a diversified business model participating in: Pharmaceuticals, Contract Manufacturing, and Medical devices. The Pharma divisions specialize in the formulation of generic drugs for human and veterinary usage and the development of medical devices used by oncologists and other medical professionals. The Manufacturing division manufactures and packages generic drugs, nutraceuticals, cosmetics, and functional food products for companies worldwide.
For further information visit the GeoPharma website at www.geopharmainc.com.
The GeoPharma, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=5384
FORWARD-LOOKING STATEMENTS
This press release may contain statements, which constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including those regarding the company and its subsidiaries' expectations, intentions, strategies and beliefs pertaining to future performance. All statements contained herein are based upon information available to the company's management as of the date hereof, and actual results may vary based upon future events, both within and without management's control. Important factors that could cause such differences are described in the company's periodic filings with the Securities and Exchange Commission.
CONTACT: GeoPharma, Inc.
Carol Dore-Falcone, Sr. VP/CFO
1-727-544-8866, ext. 227
IR@GeoPharmainc.com
NICE..
Looks like a buy sign to me.
GeoPharma Announces Fiscal Year 2010 Third Quarter Results and Conference Call
LARGO, Fla., Feb. 23, 2010
GLOBE NEWSWIRE
GeoPharma, Inc. (Nasdaq:GORX) (the "Company") announced today the results of its fiscal year 2010 third quarter which ended December 31, 2009, with revenues totaling $2,766,203 from continuing operations and a net loss basic and diluted of $(0.19) cents per share versus ($0.26) cents per share for the same period a year ago.
what they filed with the SEC is that their 10Q will be late.
Employees been working weeks now without pay!!!!Most are imigrants who either work there or get deported.Parking lots were very empty today.
hi
Why do you think it's too late?
By the way,your name is very cleaver,put a smile on my face...Check IDCN also...I dont know why but they been running hard lately.
The float is what drew me to them in the first place.I believe they only have 19 million o/s...But I could be wrong.I was so happy when I first found their ticker and get to see the company first hand but I was expecting to see 3 dollars not 30 cents..lol
I can just imagine LOL that being said at least they have a low float. (for now anyway)
Agreed,I know a person inside the company and he tells me the mgmt is very un-professional at best.He is an outside contractor who visits once a week and only deals with mgmt.The owner is a REAL peice of work..LOL
Hey it looks like GORX is trying to come off bottom you holding any shares Braden?
I'll help with what I can, no need to add me though, this maybe different company in two months (not that it will be a bad thing)The mangement team here just don't seem to know how to grow a business
Would you like to be an assistant on this board??
GORX
short interest more like 5 million
GeoPharma Inc. $ 0.35
GORX 0.04
Short Interest (Shares Short) 5,000
Days To Cover (Short Interest Ratio) 0.0
Short Percent of Float 0.06 %
Short Interest - Prior 21,200
Short % Increase / Decrease -76.42 %
Short Squeeze Ranking™
% From 52-Wk High ($ 1.20 ) -242.86 %
% From 52-Wk Low ($ 0.26 ) 25.71 %
% From 200-Day MA ($ 0.60 ) -71.43 %
% From 50-Day MA ($ 0.36 ) -2.86 %
Price % Change (52-Week) -55.90 %
Shares Float 7,844,409
Total Shares Outstanding 19,647,374
% Owned by Insiders 59.50 %
% Owned by Institutions 12.70 %
Market Cap. $ 6,876,581
Trading Volume - Today 255,744
Trading Volume - Average 934,400
Trading Volume - Today vs. Average 27.37 %
Earnings Per Share -1.63
PE Ratio
Record Date 2010-FebA
Sector Healthcare
Industry Drug Manufacturers - Major
Exchange NAS
Data Provided Without Warranty
Followers
|
9
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
90
|
Created
|
11/16/04
|
Type
|
Free
|
Moderators |
GeoPharma, Inc. is a rapidly growing Bio/Pharma company with a diversified business model participating in 3 main market segments: Specialty Pharma, Manufacturing, and Distribution. The Specialty Pharma division specializes in the formulation of generic drugs for human and veterinary usage and the development of medical devices used by oncologists and other medical professionals. The Manufacturing and Distribution divisions, manufacture, package, and distribute generic drugs, nutraceuticals, cosmetics, and functional food products for companies worldwide.
Geopharma is a company engaged in the Research, Development, Manufacturing, and Marketing of branded generic pharmaceuticals, veterinary products, health products, and functional foods. Our Company has two primary goals: to provide high-quality pharmaceuticals and health related products that improve the health of our customers, and to operate as an ethical and honorable corporate citizen. We work to fulfill these goals by enhancing our existing products as well as by developing important new products to treat a wide variety of illnesses.
GeoPharma has more than 200,000 square feet of facilities located outside Tampa, Florida. The facilities accomodate the business operations including product manufacturing, packaging/labeling, and a quality control laboratory. Manufacturing operators, Facilities and documentation comply with current good manufacturing practices (cGMP). GeoPharma is registered with both the Food and Drug administration and the Drug Enforcement administration.
GeoPharma, through American Antibiotics, has approximately 100,000 square feet of manufacturing dedicated to Beta-Lactam antibiotics in Baltimore, Maryland. This facility currently possesses several ANDA's. GeoPharma, through one of its Belcher Pharmaceuticals facilities has approximately 10,000 square feet (soon to be 20,000) dedicated to the Cephalosporin antibiotics. Currently Belcher Pharmaceuticals owns an ANDA for Cephalexin.
Transfer Agent
The Registrar and Transfer Company
10 Commerce Dr.
Account rep: Ruby Singh
Cranford, NJ
Phone: 1-800-866-1340
Innovative Health Products, Inc. develops, manufactures, markets, distributes vitamins, nutraceutical, and skin care products. IHP is more than just manufacturing services. IHP offers its customers complete turnkey solutions, including product concepts, formulations, laboratory services, package and label design, regulatory compliance and assistance in marketing and merchandising.
Breakthrough Engineered Nutrition, Inc. develops, markets, and distributes functional foods. A Wholly owned subsidiary of Geopharma, Breakthrough Engineered Nutrition, Inc. developed DEX-C20.s.
Belcher Pharmaceuticals, Inc. (Largo, FL) develops, manufactures, markets, and distributes nutraceutical, skin care, and vitamins. Belcher is a state-of-the-art 50,000 Sq. Ft. FDA-registered manufacturing, research and development facility designed to produce generic drugs and Cephalosporins.
American Antibiotics, LC develops, manufactures, markets, and Beta-Lactam antibiotics in oral and injectible forms. American Antibiotics is a Beta-Lactam facility dedicated to Amoxicillin, Ampicillin, and Penicillin production. American Antibiotics operates out of 100,000 Square Feet in Baltimore, Maryland.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |